Category Archives: 3922 – lorlatinib by Pfizer

PF-3922 Phase 1 trial

Posted on May 16, 2015 by admin

Abstract # 8018 is about a Phase 1 study of PF- 06463922 (3922). 22 patients were studied (18 ALK+ & 4 ROS1+). 17 had central nervous system (CNS) metastases and 19 had prior ALK inhibitor treatment (either 1 or 2). … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

ASCO links

Posted on May 14, 2015 by admin

Here are 18 ALK+ related abstract links related to the drugs listed below. On the ASCO website 77 abstracts refered to both “ALK” and “Inhibitor”.  When I get a chance I will write up a summary on some of the … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro | Leave a comment

Pfizer update

Posted on January 19, 2015 by admin

Pfizer announced that in 2015 the are going to start trials that combine imunitherapy (PDL-1 and PD-1) drugs with its two ALK inhibitor drugs. Pfizer is planning a potential pivotal study of PF-06463922 starting in 2015. By the end of … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, crizotinib - Xalkori from Pfizer, Imunotherapies | Leave a comment